As New Biosimilars Roll Out, Indian Biotech Group Raises Quality Concerns
This article was originally published in PharmAsia News
Leading biotech group ABLE cautioned the government that India should not become a dumping ground for low-quality biosimilar products. The group pointed at several concerns related to Cipla’s latest launch of Enbrel copies.
You may also be interested in...
Roche Lashes Out At Biosimilars Regulations In Emerging Markets, Calls For Stricter Pharmacovigilance Of Launched Products
MUMBAI - Roche - maker of blockbuster biotech products like Avastin and Mabthera - has called for a stricter regulatory and approval mechanism for biosimilars being launched in markets like India even as the European Union rolled out its draft guidelines for developing biosimilar versions of complex monoclonal antibodies Nov. 26 (EU Draft Guidelines On Biosimilar Antibodies Go Easy On Generics Firms, But Originators Need Not Panic, The Pink Sheet DAILY, Nov. 29, 2010)
Biocon Chairperson Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition: An Interview With PharmAsia News (Part 2 of 2)
Biocon Chairwoman Kiran Mazumdar Shaw has been the face of the emerging Indian biotechnology industry for decades. Under Shaw's leadership, what started in Bangalore in 1978 as a small enzyme-manufacturing unit has transformed now into a promising enterprise with partnerships with large global companies like Bristol Myers-Squibb, Pfizer and Mylan. Shaw is known for her relentless pursuit to bring out cost-effective biopharma solutions and expresses optimism about the future of biosimilars. Fresh off a deal with Pfizer for insulins, Shaw spoke at length with PharmAsia News' India Bureau about the global opportunity and Biocon's recent dealmaking with Mylan and Pfizer in part one of this interview. In this second part, she discusses the regulatory challenges for biosimilars.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.